Meril Champions Innovation with Myval Octapro THV Launch at GISE 2024 & PCR LondonValves 2024
Meril, a global leader in cutting-edge cardiovascular and structural heart solutions, is renowned for its
next-generation transcatheter heart valve technologies. Upholding its commitment to innovation, Meril continues
to drive advancements in structural heart therapies, staying true to its mission of supporting patients and
healthcare providers worldwide.
As part of this commitment, Meril is proud to announce the launch of its next-generation Myval Octapro THV, set
to debut at the upcoming GISE 2024 and London Valves 2024 conferences. The Myval Octapro THV underscores
MerilS dedication to redefining TAVR technology and shaping the future of structural heart care.
"At Meril, our commitment to developing and delivering state-of-the-art, best-in-class TAVR solutions remains
unwavering. The trust the global clinical community has placed in the Myval THV series is a testament to its
profound positive impact on patient outcomes, and we are dedicated to building on this legacy. With the launch of
the Myval Octapro THV, doctors and patients worldwide will continue to benefit from MerilS advanced
transcatheter heart valve portfolio," said Mr. Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril
Life Sciences.
Explore in-depth details of the launch of Myval Octapro THV by Meril at the upcoming GISE 2024 and London
Valves 2024 conferences. Access the complete article here:
